Aether begins Site 5 production, plans CEM blocks from Q4 FY27
Key highlights
- Aether began commercial operations in 2 pharmaceutical LSM production blocks at Site 5 in Q1 FY27.
- Aether plans to commission 2 additional Site 5 CEM blocks for semiconductor and agrochemicals contracts from Q4 FY27 onwards.
- CEM revenue rose to Rs 197 crore in Q2 FY27, accounting for 57% of total revenue.
- H1 FY27 operating revenue increased 27% to Rs 673.8 crore, while EBITDA rose 30% to Rs 213.2 crore.
powered by IRIS

Aether Industries Limited has put two Site 5 production blocks into commercial operation for a pharmaceutical large-scale manufacturing product, with operations beginning in Q1 FY27. Aether says equipment installation is being completed for two further contract and exclusive manufacturing, or CEM, blocks for semiconductor and agrochemicals contracts, to be commissioned from Q4 FY27 onwards.
Know Aether Industries inside out
Results, valuation, peers and who's buying, in one view.
What has Aether commissioned at Site 5?
Aether has commissioned two Phase 1 production blocks at Magnum, or Site 5, for a pharmaceutical large-scale manufacturing, or LSM, product. The company said commercial operations at the two blocks began in Q1 FY27, establishing the first operating capacity in the Site 5 programme.
The Site 5 update was disclosed alongside other Q2 FY27 operational developments. Aether said Site 3++ had started commercial production and was being ramped up, added six customers across its business models, and completed 11 customer and certification audits during the quarter.
The first two Site 5 blocks serve the LSM model, while the next two are designated for CEM contracts. In Q2 FY27, CEM contributed 57% of Aether's revenue, LSM accounted for 33%, and contract research and manufacturing services, or CRAMS, contributed 9%, according to the business-model disclosure.
When will Aether commission the next Site 5 blocks?
Aether plans to commission the next two Site 5 blocks for semiconductor and agrochemicals CEM contracts from Q4 FY27 onwards. Equipment installation in those blocks was being completed when the company issued its October 30, 2026 presentation, meaning the disclosed date is a commissioning plan rather than confirmation of commercial production.
Aether reported strong visibility for 14 production blocks at Site 5, but did not provide dates for the remaining 10 blocks. The disclosed schedule identifies four blocks: two pharmaceutical LSM blocks operating from Q1 FY27 and two semiconductor and agrochemicals CEM blocks expected to be commissioned from Q4 FY27 onwards.
The presentation does not disclose Site 5 capacity volumes, capital cost, customer names or contract values. At September 30, 2026, capital work-in-progress was Rs 705.2 crore, compared with Rs 506.1 crore at FY26 year-end, while property, plant and equipment was Rs 1,240.7 crore versus Rs 1,236.2 crore; Aether does not allocate these balance-sheet figures specifically to Site 5.
How is Aether's business-model mix changing?
Aether's Q2 FY27 operating revenue was Rs 347.2 crore, up 24% from Rs 280.1 crore in Q2 FY26 and above Rs 326.6 crore in Q1 FY27. The company attributed the year-on-year increase to scaling up CEM contracts and said LSM business-model contribution was being led by pricing.
CEM revenue increased by Rs 65.7 crore from Q2 FY26 to Q2 FY27, compared with increases of Rs 6 crore for CRAMS and Rs 1.4 crore for LSM. CEM and CRAMS together accounted for 66% of Q2 FY27 revenue, and management said it aims for the two models to account for 70% over the next two years.
Segment contributions also changed between the two quarters. Oil and gas accounted for 33.4% of Q2 FY27 revenue, up from 18.8% in Q2 FY26, while pharmaceuticals declined to 26.6% from 36.6% and agrochemicals fell to 7.9% from 13.3%. Aether said oil and gas and material science are expected to be the main drivers despite new product launches in pharmaceuticals and agrochemicals.
Got a follow-up? Ask IRIS
What do Aether's latest financial results show?
Aether reported H1 FY27 operating revenue of Rs 673.8 crore, up 27% from Rs 531.2 crore in H1 FY26. Earnings before interest, tax, depreciation and amortisation, or EBITDA, rose 30% to Rs 213.2 crore, while profit after tax, or PAT, increased 29% to Rs 130.7 crore.
The H1 FY27 EBITDA margin was 31.6%, compared with 30.8% in H1 FY26, and the PAT margin was 19.0%, against 18.6%. Aether attributed the financial performance to its CEM and CRAMS business models, while the presentation did not quantify any contribution from the two Site 5 blocks.
In Q2 FY27, EBITDA was Rs 110.4 crore, or 31.8% of operating revenue, compared with Rs 85.3 crore and 30.5% in Q2 FY26. Q2 PAT was Rs 68 crore, or 19.3%, versus Rs 54 crore and 18.7% a year earlier; Aether attributed the profitability change to a shift in segment mix.
What other expansion projects has Aether disclosed?
Aether spent Rs 40.601 crore on research and development in H1 FY27, equal to 6.03% of revenue from operations. The company installed 18 fume hoods in its current research and development facilities and said expansion of its new research and development centre was on track.
At Catalyst, or Site 1, Aether said ground-levelling work had been completed and building construction had commenced. The company expects construction of that building to be completed by Q1 FY28, while its presentation does not provide a commissioning date or capacity for the proposed site.
Conclusion
Aether's Site 5 programme has progressed into initial production, with two pharmaceutical LSM blocks operating from Q1 FY27 and two further blocks under equipment installation for semiconductor and agrochemicals CEM contracts. The expansion coincides with CEM revenue of Rs 197 crore in Q2 FY27 and a 27% increase in H1 FY27 operating revenue to Rs 673.8 crore.
The next disclosed milestone is commissioning of the two additional Site 5 CEM blocks from Q4 FY27 onwards. Aether has also cited visibility for 14 Site 5 production blocks and expects the Catalyst Site 1 building to be completed by Q1 FY28, but it has not disclosed schedules for the other Site 5 blocks or capacity details for either project.


